Oral minoxidil 5 mg,
does it really help with Greater hair growth than topical 5% minoxidil in male androgenetic alopecia?
research showsThe claim that oral minoxidil 5 mg produces greater hair growth than topical 5% minoxidil is rated D. Ninety men were randomized, but only 68 completed 24 weeks and were analyzed. The between-group difference in frontal terminal-hair density was 3.1 hairs/cm² (95% CI −18.2 to 21.5), P=.27, so the primary superiority endpoint failed. Only the secondary vertex photographic assessment was positive at P=.04. Comparative superiority was not demonstrated, supporting D with 29 points.
ads claimPromotion can claim that tablets are stronger than topical treatment because systemic absorption is greater. The direct 5-mg versus 5% comparison failed superiority, oral use for hair loss is off label, and systemic risks differ from topical treatment.
Useful facts when choosing a product
- The pivotal trial compared oral 5 mg once daily with topical 5% solution 1 mL twice daily for 24 weeks.
- Oral minoxidil is not an approved formulation for hair-loss treatment and is prescribed off label; this verdict is distinct from evidence for topical minoxidil.
- Hypertrichosis, headache, dizziness, tachycardia, hypotension, ankle or facial edema, and fluid retention can occur, warranting review of blood pressure, pulse, and cardiovascular history.
- Rapid weight gain, dyspnea, chest pain, syncope, persistent tachycardia, or edema requires stopping treatment and prompt medical evaluation.
What the research actually shows
A Brazilian single-center double-blind trial randomized 90 men with androgenetic alopecia to oral minoxidil 5 mg once daily or topical 5% minoxidil twice daily, but analyzed 68 who completed 24 weeks. The primary frontal terminal- and total-hair-density comparisons failed at P=.27 and P=.32. Counted vertex terminal and total density also failed at P=.09 and P=.32. Photographic assessment was positive only at the vertex, with a 24% difference and P=.04, while the frontal photograph result was P=.24. A separate 65-person trial likewise found no significant hair-diameter difference between oral 1 mg and standard topical treatment.
Why this is classified as D (29)
The primary frontal terminal-hair-density superiority endpoint failed at P=.27 in 68 actual completers, and only the secondary vertex photographic assessment was positive at P=.04. Primary failure with secondary-only positivity supports D with 29 points.
Counterpoint. Oral treatment may be an alternative when topical use is difficult or irritating, but the decision concerns convenience and systemic safety rather than proven superior efficacy.
Rejudgment record. Cross-check applied — Distinguished 90 enrolled men from 68 actual completers and prioritized failure of the frontal terminal-hair-density primary superiority endpoint over positivity on a secondary vertex photographic assessment
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Superior frontal hair growth versus topical 5% minoxidil | D | The primary terminal-hair-density analysis failed at P=.27. |
| Superior counted vertex hair density versus topical 5% minoxidil | D | Terminal-hair P=.09 and total-hair P=.32 were both nonsignificant. |
| Improved vertex photographic assessment versus topical 5% minoxidil | C | A 24% difference at P=.04 was positive but secondary and does not override primary superiority failure. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Penha MA et al. 2024 | Single-center randomized double-blind oral-versus-topical head-to-head trial | 68 | Brazilian university academic research; no commercial manufacturer funding reported | Primary: change in terminal and total hair density at frontal and vertex scalp | Frontal terminal-hair difference 3.1 hairs/cm², P=.27, failed superiority; only secondary vertex photographic assessment was positive at P=.04. | Key direct superiority randomized trial |
| Asilian A et al. 2024 | Randomized oral-versus-topical head-to-head trial | 65 | Iranian university academic research | Six-month hair diameter, photographic assessment, and satisfaction | The hair-diameter difference between oral 1 mg and standard topical treatment was nonsignificant and did not show oral superiority. | Supportive head-to-head evidence at a different oral dose |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-24).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Oral minoxidil 5 mg x superior hair growth versus topical 5% minoxidil — Evidence Grade D·29. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/skin-hair/oral-minoxidil-5mg-superior-topical-5-percent-male-pattern-hair-loss/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.